Translational Oncology (Jan 2021)

Lymphocyte subsets in haematological patients with COVID-19: Multicentre prospective study

  • Elżbieta Kalicińska,
  • Donata Szymczak,
  • Iga Andrasiak,
  • Aleksandra Bogucka-Fedorczuk,
  • Aleksander Zińczuk,
  • Wojciech Szymański,
  • Monika Biernat,
  • Marcin Rymko,
  • Grażyna Semeńczuk,
  • Paula Jabłonowska,
  • Justyna Rybka,
  • Krzysztof Simon,
  • Tomasz Wróbel

Journal volume & issue
Vol. 14, no. 1
p. 100943

Abstract

Read online

The role of immune dysregulation in the course and prognosis of COVID-19 is not clearly established. In particular, immune status in specific populations such as haematological patients, who have an impaired immunological system, has not been described so far. Here, we performed a comprehensive analysis of peripheral blood lymphocyte subsets in 27 SARS-CoV-2-infected patients, including 16 patients with haematological malignancies. We identified T cell subpopulations, B cells, NK cells and TCR α/ß and ɣ/ƍ-expressing T cells during COVID-19 infection, with significant changes observed in immune profiles during the course of disease, especially in haematological patients. We observed an increase in activated T lymphocytes (CD3+HLA-DR+ and CD3+CD8+HLA-DR+) in the early stages of SARS-CoV-2 infection with a concomitant decrease in the CD4/CD8 ratio in haematological patients compared to non-haematological patients affected by COVID-19. We also found a decrease in ɣ/ƍ T cells in both studied groups of patients, with lower numbers of CD25+ T cells and CD16+CD56+ NK cells in haematological patients compared to non-haematological patients with COVID-19. Our findings demonstrate, for the first time, impaired adaptive immunity in patients with haematological malignancies infected with COVID-19, resulting in impaired cellular immune responses to SARS-CoV-2. This warrants further investigation of this disease group in COVID-19 patient cohorts

Keywords